Search

Displaying results 2871 - 2880 of 5302 in total
  1. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

  2. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes. … Removing eschar (a process also known as debridement) through surgical procedures can lead to significant trauma, major blood and heat loss and adjacent tissue damage.

  3. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.

  4. Drug

    Ropivacaine

    go.drugbank.com/drugs/DB00296
    ApprovedInvestigational

    Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin.

  5. Drug

    Acetophenazine

    go.drugbank.com/drugs/DB01063
    Approved

    Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking.

  6. Drug

    Ruplizumab

    go.drugbank.com/drugs/DB06475
    Investigational

    Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

  7. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237] This drug was first approved in Japan on 25 March 2013.

  8. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

  9. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in

  10. Drug

    Ceftaroline fosamil

    go.drugbank.com/drugs/DB06590
    ApprovedInvestigational

    Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections. Community-acquired bacterial pneu...